Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 2
1(25.0%)
4Total
N/A(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03925389Recruiting

Outcome Analysis in Septorhinoplasty

Role: collaborator

NCT05061069Not ApplicableCompleted

Vestibular Infants Screening-Flanders

Role: collaborator

NCT03705403Phase 2Terminated

IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study

Role: collaborator

NCT05727605Not ApplicableRecruiting

Neurocognition After Radiotherapy in CNS- and Skull-base Tumors

Role: collaborator

NCT03628482Not ApplicableCompleted

Pulsed Radiofrequency to Relieve Knee Pain

Role: lead

All 5 trials loaded